Is there a generic version of Sotyktu (deucravacitinib)?
No generic for Sotyktu (deucravacitinib) is indicated in the information available here. If a generic is approved, it would typically come after key patent and exclusivity barriers for the branded product have expired, along with required FDA approval.
When would a generic Sotyktu be expected (patent/exclusivity timing)?
Generic availability usually depends on when patents and any related exclusivity for deucravacitinib expire, plus how long it takes for applicants to complete FDA review. You can check the current patent-expiry and litigation landscape for deucravacitinib on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/brands/sotyktu/
Who can make a generic Sotyktu, and what would it be labeled as?
A generic competitor would be an FDA-approved “deucravacitinib” product (same active ingredient). If an approval happens before all barriers are fully cleared, it generally does not lead to marketing until the relevant legal protections end.
Could there be a copycat before a full “generic” is approved?
Depending on the status of patents and regulatory pathways, companies may file applications (for example, under the Hatch-Waxman framework for generics) before branded exclusivity ends, but that doesn’t mean the product can be marketed immediately. Final launch timing still hinges on legal and FDA approval outcomes.
How to get the most accurate answer for your location and timing
If you’re trying to know whether a generic is actually available now (or when it will start showing up at pharmacies), the fastest path is to check:
- your country’s medicines database (for availability),
- the FDA’s “drugs@FDA” database (for approval status),
- and deucravacitinib patent/exclusivity tracking on DrugPatentWatch.com.
Sources
[1] https://www.drugpatentwatch.com/p/brands/sotyktu/